Discover how the Human Papillomavirus (HPV) vaccine plays a critical role in preventing cervical cancer.
NCI
04 Oct, 2024
Human Papillomavirus (HPV) Vaccine
HPV is a double-stranded DNA virus that has long been known to be the causative agent for genital warts and has recently been determined to be responsible for cervical cancers.
Cervical Cancer:
This is cancer of the uterine cervix, with 90% of the cancers being squamous cell in origin. Persistent infection of the cervix with HPV is the primary cause of cervical cancer.
Risk Factors of Cervical Cancer:
HPV infection is contracted mainly through sexual behavior, which includes multiple sexual partners, new partners, partner sex history, and the age of onset of sexual intercourse. There are over 100 types of HPV, with types 16 and 18 accounting for 70% of cervical cancers, and the remaining caused by types 31 and 33.
Prevention:
Vaccination:
Vaccination against Human Papilloma Virus disease should be done before the onset of sexual activity for optimal protection but can be used in sexually active groups to prevent multiple or persistent infections.
Three prophylactic HPV vaccines directed against high-risk HPV types are currently available: the quadrivalent vaccine, the bivalent vaccine, and the nonavalent vaccine.
The quadrivalent and nonavalent vaccines offer comparable immunogenicity, efficacy, and effectiveness for the prevention of cervical cancer, which is mainly caused by HPV types 16 and 18.
Target Population:
The recommended primary target population for HPV vaccination is girls aged 9–14 years prior to becoming sexually active.